Slide 1: Next Generation Natural Killer Cells Engineered to Beat Cancer
5 December 2022 NEXT GENERATION Natural Killer Cells Engineered to Beat Cancer Exhibit 99.2
Slide 2: Forward-looking statements
Forward-looking statements This presentation contains forward‐looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, regarding future events and the future results of the company that are based on current expectations, estimates, forecasts, and projections ab
Slide 3: Next generation platform: CAR NK cells driving a revolution in off-the-shelf cell therapy
Next generation platform built for: CAR NK cells driving a revolution in off-the-shelf cell therapy Allogeneic, off-the-shelf, and on demand Industrialized manufacturing Outpatient administration Targeting receptor CAR NK Cell OX40 costimulatory domain CD3ζ signaling moiety CAR membrane bound IL-15
Slide 4: NKX019: Key topics for discussion
Best response for 6 additional patients treated since April update Follow-up on patients from April update, including multiple patients with durability beyond 6 months Tolerability and clinical impact of additional cycles of NKX019 Deepening Consolidation Retreatment Outpatient administration in mul
Slide 5: NKX019 for the Treatment of Relapsed / Refractory B-Cell Malignancies
NKX019 for the Treatment of Relapsed / Refractory B-Cell Malignancies Clinical Data as of 28 November 2022
Slide 6: CAR T-cell therapy is not accessible to most patients with NHL
CAR T-cell therapy is not accessible to most patients with NHL Only 20-30% of patients with LBCL that can benefit from cell therapy receive it Potential for toxicity requires close proximity to an intensive care unit Need for specialized sites as >25% of patients require ICU care Grade 3+ CRS: 13 to
Slide 7: NKX019 for B-cell malignancies: A multicenter, open-label, phase 1 study
r/r CD19+ B-cell malignancies Received >2 prior lines of therapy ECOG PS 0 or 1 CAR T-cell therapy naïve (dose-finding phase) Endpoints: Safety and tolerability Anti-tumor activity Pharmacokinetics NKX019 for B-cell malignancies: A multicenter, open-label, phase 1 study NKX019 3 doses per 28-day cyc
Slide 8: Patients treated with NKX019 were heavily pre-treated and had a poor prognosis
Patients who were treated with NKX019 were heavily pre-treated and had a poor prognosis 50% 4 7 of 14 patients with NHL had aggressive LBCL Median lines of prior therapy NKX019 Total (N=19) Age, median (range) 59 (21-82) Baseline ECOG PS 1 13 Australia/US 13/6 Diagnosis Large B cell lymphoma (LBCL)#
Slide 9: NKX019 was well-tolerated up to 1.5 B cells / dose
NKX019 was well-tolerated up to 1.5 B cells / dose No ICANS / neurotoxicity, GVHD, Grade 5 or dose-limiting toxicities One (5%) Grade ≥ 3 infection No treatment-related AEs leading to discontinuation of NKX019 Myelosuppression, consistent with standard lymphodepletion, was the most common Grade ≥ 3
Slide 10: A minority of patients experienced transient and manageable infusion-related effects
A minority of patients experienced transient and manageable infusion-related effects 5/19 patients (26%) developed fever within 8 hours that resolved within 24 hours In contrast, CAR T-cell therapy–associated CRS has a median onset of 2-5 days and a median duration of 5-8 days Grade 1/2 infusion-rel
Slide 11: Peak cytokine levels were marginally above baseline for most patients
Peak IL-6, IFNγ, IL-10, and IL-8 levels were marginally above baseline throughout treatment for most patients Severe (Grade > 3) CRS in those receiving CAR T-cell therapies is generally associated with ~100-fold changes of multiple serum cytokines No Grade > 3 CRS observed to date with NKX019 No ass
Slide 12: NKX019 showed monotherapy activity across multiple histologies
NKX019 showed monotherapy activity across multiple histologies 300 M Cells × 3 Doses 1 B Cells × 3 Doses 1.5 B Cells × 3 Doses ORR (CR, PR) CR ORR (CR, PR) CR ORR (CR, PR) CR All NHL 2/4 1/4 5/6 (83%) 4/6 (67%) 3/4 (75%) 3/4 (75%) LBCL# 1/3 0/3 1/2 1/2 1/2 1/2 MCL - - 1
Slide 13: NKX019 monotherapy elicited complete responses with early durability across NHL histologies
NKX019 monotherapy elicited complete responses with early durability across NHL histologies; most responses occurred after a single cycle 1 1.5 B FL CR 2 1.5 B LBCL CR 3 1.5 B FL CR 4 1.5 B LBCL SD 5 1.0 B LBCL CR 6 1.0 B MZL CR 7 1.0 B FL CR 8 1.0 B MCL CR 9 1.0 B FL PR 10 1.0 B LBCL SD 11 300 M F
Slide 14: Nearly every patient with NHL treated with NKX019 experienced tumor reduction
Nearly every patient with NHL treated with NKX019 experienced tumor reduction Notes: 1. Tumor size is calculated as sum of the product of the perpendicular diameters (SPD). 2. One patient discontinued due to clinical progression without SPD assessment. 3. One patient did not have any target lesions
Slide 15: Higher cell doses correlated with higher peak concentration (Cmax)
Higher cell doses correlated with higher peak measured concentration (Cmax) Peak concentration trended higher in patients achieving CR Higher peak concentrations of NKX019 correlated with complete responses and higher doses of NKX019 6.7 = Lower limit of quantification Cmax, given as transgene copie
Slide 16: Successive rounds of NKX019 are feasible and effective
Successive rounds of NKX019 are feasible and effective at achieving clinical responses Median interval between treatment cycles was 8 days Lymphodepletion was given at the beginning of each 28-day cycle of therapy and was well-tolerated 40% of eligible patients received NKX019 in the outpatient sett
Slide 17: CAR T-naïve, CAR T-experienced and rituximab combination expansion cohorts
CAR T-cell therapy–naïve LBCL cohort Improved access and favorable safety profile Comparable CR rate to autologous CAR T CAR T-cell therapy–experienced LBCL cohort CD19 expression persists in >90% of those who fail CAR T-cell therapy; outcomes for these patients are poor1 NKX019 offers NK-driven cyt
Slide 18: NKX019 remains on track for potential registration-enabling studies
NKX019 remains on track for potential registration-enabling studies Allogeneic and off-the-shelf cell therapy to improve patient access Evaluation of monotherapy activity as well as in combination with rituximab Strong cash position: $395 million as of September 30, with runway into 2025 Clinical da
Slide 19: NKX019 monotherapy continues to be well-tolerated with promising anti-tumor activity
Building on earlier data, NKX019 monotherapy continues to be well-tolerated with promising anti-tumor activity Six additional patients with r/r NHL have been treated since prior data cut-off Earlier reported PR deepened to CR CR rate improved to 70% from previous update of 50% On-demand availability